A Phase 3 interventional study of Lazertinib and Amivantamab in Carcinoma, Non-Small-Cell Lung, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 249 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung — 6 open to participants now, 11 under way, 2 of them phase 3. lazertinib · Carcinoma, Non-Small-Cell Lung.
Among the 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung, this one is the 2nd largest by enrollment, is one of 3 that started in 2021, is one of 3 in phase 3, reaches primary completion later than 0 of the 10 other live ones, and was the 8th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →6 of the 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States, Canada, China and 3 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Belgium, Finland and 11 more countries
Ages 18+
Sehhoon Park · Sites in Korea, Republic of
Ages 19+
Sung Yong Lee · Sites in Korea, Republic of
Ages 18+
Konkuk University Medical Center · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
lazertinib: first FDA approval 2024 (LAZCLUZE), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 14 · Phase 3 3
First in 2017; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 776 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 67 across the 20 interventional studies. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
36 studies in Carcinoma, Non-Small-Cell Lung by Johnson & Johnson: 7 open now, 18 under way, 4 of them phase 3. Of 15 finished, 7 (47%) have results posted.
Among the 36 studies in Carcinoma, Non-Small-Cell Lung by Johnson & Johnson, this one is the 2nd largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2021, is one of 4 in phase 3, reaches primary completion later than 1 of the 17 other live ones, and was the 21st registered.
Johnson & Johnson’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2012.
1 of the studies testing lazertinib in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04077463Janssen Research & Development, LLCA Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer | 2027-02-12 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing lazertinib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Johnson & Johnson’s 36 in Carcinoma, Non-Small-Cell Lung:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy of adding lazertinib to amivantamab, carboplatin, and pemetrexed (LACP/ACP-L dosing strategies) and amivantamab, carboplatin and pemetrexed (ACP) compared with carboplatin and pemetrexed (CP) in participants with locally advanced or metastatic epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R substitution non-small cell lung cancer (NSCLC) after osimertinib failure. The purpose of the extension cohort is to further describe the safety and efficacy for the ACP-L dosing schedule versus ACP with additional data. After completion of the primary analysis, the study may eventually transition to an open-label extension (OLE) or long-term extension (LTE) phase during which participants will have the option to continue their assigned treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LACP dosing (study start until 6 November 2022): Participants will receive Lazertinib orally along with Amivantamab, Pemetrexed, and Carboplatin as IV infusion starting on Cycle 1 Day 1 for 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab, Pemetrexed and Lazertinib as maintenance until disease progression. ACP-L dosing (from 7 November 2022 until study completion): Participants will receive Amivantamab, Pemetrexed, and Carboplatin starting on Cycle 1 Day 1 for 4 cycles. Lazertinib in ACP-L will start on Cycle 5 Day 1 or sooner if carboplatin is discontinued before cycle 4 (each cycle consists of 21 days). Beginning with Cycle 5 Day 1, participants will receive Amivantamab, Pemetrexed and Lazertinib as maintenance until disease progression.
Drug: Lazertinib · Drug: Amivantamab · Drug: Pemetrexed · Drug: Carboplatin
Participants will receive Pemetrexed in combination with Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Pemetrexed as maintenance until disease progression.
Drug: Pemetrexed · Drug: Carboplatin
Participants will receive Amivantamab, Pemetrexed, and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab and Pemetrexed as maintenance until disease progression.
Drug: Amivantamab · Drug: Pemetrexed · Drug: Carboplatin
Participants will receive Amivantamab, Pemetrexed and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days), Lazertinib will start on C5D1 or sooner if carboplatin is discontinued earlier). After 4 cycles, participants will receive Pemetrexed, Amivantamab, Lazertinib as maintenance until disease progression.
Drug: Lazertinib · Drug: Amivantamab · Drug: Pemetrexed · Drug: Carboplatin
Participants will receive Amivantamab, Pemetrexed, and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab and Pemetrexed as maintenance until disease progression.
Drug: Amivantamab · Drug: Pemetrexed · Drug: Carboplatin
Lazertinib will be administered orally.
Also known as: JNJ-73841937, YH-25448
Amivantamab will be administered as an IV infusion.
Also known as: JNJ-61186372
Pemetrexed will be administered as an IV infusion.
Carboplatin will be administered as an IV infusion.
Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)
PFS is defined as the time from randomization until the date of objective disease progression or death, whichever came first, as assessed by BICR according to RECIST version 1.1. Progressed disease: Sum of diameters increased by greater than or equal to (\>=)20 percent (%) and \>=5 millimeter (mm) from nadir (including baseline if it was smallest sum).
Time frame: From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)
Main Study + Extension Cohort: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
Follow-up for the extension cohort is still ongoing and thus results from the analysis that includes the extension cohort will be reported up on study completion.
Time frame: up to 4 years 10 months
Main Study + Extension Cohort: Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review
Time frame: Up to 4 years 10 months
Main Study+ Extension Cohort: Objective Response Rate as Assessed by Blinded Independent Central Review
Time frame: Up to 4 years 10 months
Main Study+ Extension Cohort: Overall Survival
Time frame: Up to 4 years 10 months
Main Study+ Extension Cohort: Duration of Response as Assessed by Blinded Independent Central Review
Time frame: Up to 4 years 10 months
Main Study+ Extension Cohort: Time to Subsequent Therapy
Time frame: Up to 4 years 10 months
Main Study+ Extension Cohort: Progression-free Survival (PFS) After First Subsequent Therapy (PFS2)
Time frame: Up to 4 years 10 months
Main Study+ Extension Cohort: Time to Symptomatic Progression
Time frame: Up to 4 years 10 months
Main Study+ Extension Cohort: Intracranial Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review
Time frame: Up to 4 years 10 months
Main Study: Number of Participants With Adverse Events (AEs)
Time frame: Up to 4 years 10 months
Main Study+ Extension Cohort: Number of Participants With Adverse Events (AEs) by Severity
Time frame: Up to 4 years 10 months
Main Study+ Extension Cohort: Number of Participants With Clinical Laboratory Abnormalities
Time frame: Up to 4 years 10 months
Main Study+ Extension Cohort: Serum Concentration of Amivantamab
Time frame: Up to 4 years 10 months
Main Study+ Extension Cohort: Plasma Concentration of Lazertinib
Time frame: Up to 4 years 10 months
Main Study + Extension Cohort: Number of Participants With Serum Anti-amivantamab Antibodies
Time frame: Up to 4 years 10 months
Main Study+ Extension Cohort: Change From Baseline With Non-Small Cell Lung Cancer - Symptom Assessment Questionnaire (NSCLC-SAQ)
Time frame: Up to 4 years 10 months
Main Study+ Extension Cohort: Change From Baseline With European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)
Time frame: Up to 4 years 10 months
Main Study+ Extension Cohort: Change From Baseline With Patient-Reported Outcomes Measurement Information System -Physical Function (PROMIS-PF)
Time frame: Up to 4 years 10 months
A total of 657 participants were enrolled in the main study. During the study, a separate open-label randomized extension cohort was added. A total of 119 participants were enrolled into the extension cohort. Main study results are alone reported for primary completion date (PCD; 10-July-2023).
| Milestone | Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) | Main Study: Arm B: Carboplatin + Pemetrexed (CP) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) | Extension Cohort: All Participants (Arm A2 [ACP-L] + C2 [ACP]) |
|---|---|---|---|---|
| Started | 263 | 263 | 131 | 119 |
| Treated (safety analysis set) | 263 | 243 | 130 | 119 |
| Completed | 67 | 65 | 26 | 0 |
| Not completed | 196 | 198 | 105 | 119 |
| Withdrew: Withdrawal by subject | 9 | 29 | 6 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 |
| Withdrew: Study participation ongoing | 186 | 169 | 99 | 119 |
PFS is defined as the time from randomization until the date of objective disease progression or death, whichever came first, as assessed by BICR according to RECIST version 1.1. Progressed disease: Sum of diameters increased by greater than or equal to (\>=)20 percent (%) and \>=5 millimeter (mm) from nadir (including baseline if it was smallest sum).
| months | Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) | Main Study: Arm B: Carboplatin + Pemetrexed (CP) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) |
|---|---|---|---|
| Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) | 8.31 (6.77 to 9.10) | 4.17 (4.04 to 4.44) | 6.28 (5.55 to 8.41) |
Follow-up for the extension cohort is still ongoing and thus results from the analysis that includes the extension cohort will be reported up on study completion.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over From Cycle 1 Day 1 up to 1 year 7 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) | 69/263 (26.2%) | 137/263 (52.1%) | 261/263 (99.2%) |
| Main Study: Arm B: Carboplatin + Pemetrexed (CP) | 65/263 (24.7%) | 49/243 (20.2%) | 222/243 (91.4%) |
| Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) | 27/131 (20.6%) | 42/130 (32.3%) | 129/130 (99.2%) |
| Event | Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) | Main Study: Arm B: Carboplatin + Pemetrexed (CP) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) |
|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 22/263 | 5/243 | 4/130 |
| NeutropeniaBlood and lymphatic system disorders | 21/263 | 6/243 | 2/130 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 20/263 | 5/243 | 2/130 |
| LeukopeniaBlood and lymphatic system disorders | 10/263 | 1/243 | 0/130 |
| Infusion Related ReactionInjury, poisoning and procedural complications | 9/263 | 0/243 | 2/130 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/263 | 2/243 | 4/130 |
| PneumoniaInfections and infestations | 8/263 | 5/243 | 0/130 |
| AnaemiaBlood and lymphatic system disorders | 8/263 | 2/243 | 2/130 |
| NauseaGastrointestinal disorders | 8/263 | 0/243 | 1/130 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 7/263 | 0/243 | 1/130 |
| Event | Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) | Main Study: Arm B: Carboplatin + Pemetrexed (CP) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) |
|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 173/263 | 98/243 | 73/130 |
| ThrombocytopeniaBlood and lymphatic system disorders | 156/263 | 69/243 | 57/130 |
| Infusion Related ReactionInjury, poisoning and procedural complications | 142/263 | 1/243 | 74/130 |
| AnaemiaBlood and lymphatic system disorders | 141/263 | 96/243 | 50/130 |
| ParonychiaInfections and infestations | 132/263 | 1/243 | 48/130 |
| NauseaGastrointestinal disorders | 130/263 | 90/243 | 58/130 |
| RashSkin and subcutaneous tissue disorders | 125/263 | 12/243 | 56/130 |
| StomatitisGastrointestinal disorders | 120/263 | 21/243 | 41/130 |
| LeukopeniaBlood and lymphatic system disorders | 106/263 | 67/243 | 37/130 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 104/263 | 21/243 | 29/130 |
Only main study (N=657) results are reported, thus column "Total participants" presents main study data. Per protocol, extension cohort analysis was not included in main study primary analysis. Extension cohort results will be reported later, upon analysis completion, at which point arms A2 and C2 details will be reported. For reporting purpose of extension cohort at this time since data is still not available, single combined arm for extension cohort (A2/C2) is presented with '0' participants.
| Age, Continuous(years) | Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) | Main Study: Arm B: Carboplatin + Pemetrexed (CP) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) | Extension Cohort: All Participants (Arm A2 [ACP-L] + C2 [ACP]) | Total |
|---|---|---|---|---|---|
| Mean | 60.3 ± 10.96 | 60.6 ± 10.13 | 61.2 ± 10.06 | — | 60.6 ± 10.44 |
| Sex: Female, Male(Participants) | Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) | Main Study: Arm B: Carboplatin + Pemetrexed (CP) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) | Extension Cohort: All Participants (Arm A2 [ACP-L] + C2 [ACP]) | Total |
|---|---|---|---|---|---|
| Female | 168 | 157 | 81 | — | 406 |
| Male | 95 | 106 | 50 | — | 251 |
| Ethnicity (NIH/OMB)(Participants) | Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) | Main Study: Arm B: Carboplatin + Pemetrexed (CP) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) | Extension Cohort: All Participants (Arm A2 [ACP-L] + C2 [ACP]) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 22 | 23 | 9 | — | 54 |
| Not Hispanic or Latino | 234 | 234 | 118 | — | 586 |
| Unknown or Not Reported | 7 | 6 | 4 | — | 17 |
| Race (NIH/OMB)(Participants) | Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) | Main Study: Arm B: Carboplatin + Pemetrexed (CP) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) | Extension Cohort: All Participants (Arm A2 [ACP-L] + C2 [ACP]) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 3 | 1 | — | 4 |
| Asian | 125 | 127 | 63 | — | 315 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | — | 0 |
| Black or African American | 4 | 1 | 3 | — | 8 |
| White | 129 | 123 | 60 | — | 312 |
| More than one race | 0 | 2 | 0 | — | 2 |
| Unknown or Not Reported | 5 | 7 | 4 | — | 16 |
| Region of Enrollment(Participants) | Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) | Main Study: Arm B: Carboplatin + Pemetrexed (CP) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) | Extension Cohort: All Participants (Arm A2 [ACP-L] + C2 [ACP]) | Total |
|---|---|---|---|---|---|
| ARGENTINA | 5 | 6 | 0 | — | 11 |
| BELGIUM | 10 | 3 | 3 | — | 16 |
| BRAZIL | 10 | 13 | 6 | — | 29 |
| BULGARIA | 0 | 1 | 1 | — | 2 |
| CANADA | 7 | 11 | 4 | — | 22 |
| CHINA | 45 | 40 | 15 | — | 100 |
| CZECH REPUBLIC | 1 | 1 | 1 | — | 3 |
| FRANCE | 14 | 18 | 7 | — | 39 |
| GERMANY | 3 | 4 | 0 | — | 7 |
| HONG KONG | 0 | 2 | 0 | — | 2 |
| INDIA | 14 | 8 | 4 | — | 26 |
| ISRAEL | 6 | 4 | 3 | — | 13 |
| ITALY | 20 | 19 | 11 | — | 50 |
| JAPAN | 17 | 24 | 9 | — | 50 |
| MALAYSIA | 4 | 5 | 8 | — | 17 |
| MEXICO | 5 | 4 | 2 | — | 11 |
| NETHERLANDS | 1 | 4 | 2 | — | 7 |
| POLAND | 1 | 9 | 4 | — | 14 |
| PORTUGAL | 4 | 2 | 1 | — | 7 |
| RUSSIAN FEDERATION | 1 | 0 | 0 | — | 1 |
| SOUTH KOREA | 25 | 21 | 17 | — | 63 |
| SPAIN | 30 | 24 | 13 | — | 67 |
| SWEDEN | 3 | 1 | 0 | — | 4 |
| TAIWAN | 10 | 17 | 7 | — | 34 |
| TURKEY | 10 | 5 | 4 | — | 19 |
| UNITED KINGDOM | 8 | 10 | 2 | — | 20 |
| UNITED STATES | 9 | 7 | 7 | — | 23 |
Showing the first 100 of 249 sites across 29 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Nov 2021 to primary completion in Jul 2023, 19 months.
Results were first posted in Apr 2025, 1 year 9 months after primary completion. A results delay was requested in Jul 2024.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 19 months is below that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lazertinib · Amivantamab
Carcinoma, Non-Small-Cell Lung →
Janssen Research & Development, LLC →